5/9/2013

Nuclea Biotechnologies secured an additional $4.2 million in Series D financing, bringing the company's total for that round to $40.3 million. The Massachusetts-based firm will use some of the money to launch its fatty acid synthase assays and other diagnostic tests.

Related Summaries